Show simple item record

dc.contributor.authorRepik, Alexander
dc.contributor.authorPincus, Steve E.
dc.contributor.authorGhiran, Ionita
dc.contributor.authorNicholson-Weller, Anne
dc.contributor.authorAsher, Damon R.
dc.contributor.authorCerny, Anna M.
dc.contributor.authorCasey, Leslie S.
dc.contributor.authorJones, S. M.
dc.contributor.authorJones, Stephen N.
dc.contributor.authorMohamed, Nehal
dc.contributor.authorKlickstein, Lloyd B.
dc.contributor.authorSpitalny, George L.
dc.contributor.authorFinberg, Robert W.
dc.date2022-08-11T08:09:59.000
dc.date.accessioned2022-08-23T16:51:28Z
dc.date.available2022-08-23T16:51:28Z
dc.date.issued2005-04-06
dc.date.submitted2008-06-18
dc.identifier.citation<p>Clin Exp Immunol. 2005 May;140(2):230-40. <a href="http://dx.doi.org/10.1111/j.1365-2249.2005.02764.x">Link to article on publisher's site</a></p>
dc.identifier.issn0009-9104 (Print)
dc.identifier.doi10.1111/j.1365-2249.2005.02764
dc.identifier.pmid15807846
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41865
dc.description.abstractComplement receptor 1 (CR1) on the surface of human erythrocytes facilitates intravascular clearance of complement-opsonized pathogens. The need for complement activation can be circumvented by directly coupling the organism to CR1 using a bispecific monoclonal antibody heteropolymer (HP). Lack of a functional homologue to CR1 on mouse erythrocytes has made it difficult to study HP-dependent clearance of pathogens in small animals. We have developed a transgenic mouse that expresses human CR1 on erythrocytes. CR1 antigen is of appropriate size and in a clustered distribution as confirmed by immunoblotting and fluorescence microscopy, respectively. HP that immobilized bacteriophage PhiX174 prototype pathogen to erythrocyte CR1 of the transgenic mice increased the rate of clearance of the virus compared with HP that bound bacteriophage, but not CR1. This transgenic mouse model will allow evaluation of different HPs for their in vivo efficacy and potential as human therapeutics.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15807846&dopt=Abstract ">Link to article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809366/
dc.subjectAnimals
dc.subjectAntibodies, Bispecific
dc.subjectAntigen-Antibody Complex
dc.subjectBacteriophage phi X 174
dc.subject*Blood-Borne Pathogens
dc.subject*Disease Models, Animal
dc.subjectDose-Response Relationship, Immunologic
dc.subjectErythrocytes
dc.subjectHumans
dc.subjectMice
dc.subjectMice, Inbred C57BL
dc.subjectMice, Transgenic
dc.subjectMicroscopy, Fluorescence
dc.subjectPapio
dc.subjectReceptors, Complement
dc.subjectImmunology and Infectious Disease
dc.titleA transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1)
dc.typeJournal Article
dc.source.journaltitleClinical and experimental immunology
dc.source.volume140
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/467
dc.identifier.contextkey533181
html.description.abstract<p>Complement receptor 1 (CR1) on the surface of human erythrocytes facilitates intravascular clearance of complement-opsonized pathogens. The need for complement activation can be circumvented by directly coupling the organism to CR1 using a bispecific monoclonal antibody heteropolymer (HP). Lack of a functional homologue to CR1 on mouse erythrocytes has made it difficult to study HP-dependent clearance of pathogens in small animals. We have developed a transgenic mouse that expresses human CR1 on erythrocytes. CR1 antigen is of appropriate size and in a clustered distribution as confirmed by immunoblotting and fluorescence microscopy, respectively. HP that immobilized bacteriophage PhiX174 prototype pathogen to erythrocyte CR1 of the transgenic mice increased the rate of clearance of the virus compared with HP that bound bacteriophage, but not CR1. This transgenic mouse model will allow evaluation of different HPs for their in vivo efficacy and potential as human therapeutics.</p>
dc.identifier.submissionpathoapubs/467
dc.contributor.departmentProgram in Molecular Medicine
dc.contributor.departmentDepartment of Medicine
dc.source.pages230-40


This item appears in the following Collection(s)

Show simple item record